VivoSim Labs holds 2026 annual meeting, approves equity plan increase and warrant terms

VivoSim Labs, Inc. held its 2026 Annual Meeting of Stockholders on September 30, 2026, according to a Form 8-K filed with the SEC. Of the 16,586,495 shares outstanding as of the August 13, 2026 record date, 6,180,635 shares, or 37.26%, were represented at the meeting, forming a quorum.¹

Shareholders voted to elect Keith Murphy and Adam Stern as Class III directors, with each set to serve until the 2029 Annual Meeting of Stockholders and until a successor is elected and qualified.¹

They also ratified Rosenberg Rich Baker Berman P.A. to continue as the company's independent registered public accounting firm through the fiscal year ending March 31, 2027, a measure that passed with 92.51% of votes cast.¹ A separate advisory vote on executive pay was approved with 76.33% support.

Investors also approved an amendment letting the board carry out a reverse stock split of the common stock at any point through September 30, 2027, at a ratio between 1-for-5 and 1-for-20 to be set at the board's discretion, without cutting the authorized share count or requiring another stockholder vote, a measure that drew 74.12% approval.¹

A plan amendment increasing the equity incentive pool passed with 72.52% support: the restated 2022 plan will add 3,165,000 shares available for issuance along with other clarifying changes.¹

Finally, in a vote tied to Nasdaq rules, stockholders approved the issuance of 4,705,883 shares tied to warrants from the company's July 2026 private placement, plus a cut in the exercise price of warrants issued May 13, 2024, from $9.60 to $0.85 per share, with 77.87% approval.¹

The filing was signed by Executive Chairman Keith Murphy on October 6, 2026.